Kezar Life Sciences, Inc. (“Kezar” or the “Company”) (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, announces that it has received an unsolicited, non-binding proposal from Concentra Biosciences, LLC (“Concentra”), a Delaware limited liability company, to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per share, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar’s development programs or intellectual property.
Read the full article: Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal //
Source: https://www.businesswire.com/news/home/20241010708833/en/Kezar-Confirms-Receipt-of-Unsolicited-Non-Binding-Acquisition-Proposal